Angiosyn is developing angiogenesis therapeutics for the treatment of ophthalmic diseases.

History:

Angiosyn was acquired by Pfizer in 2005.

Employment

Email:

Fax:

Mail:

General Info:

Ticker:

Employees:

Regions:
Southern California

Research Focus:
Disease Therapeutics-Research Therapeutics-Development

 

Profiles:

 

News:

Keywords: 

Strategic Partnerships: